Tissue-sparing laser therapy successfully treats DME

December 19, 2011

Iridex Corporation have announced the results of a 10 year study confirming the safety and efficacy of using MicroPulse laser therapy for the treatment of diabetic macular oedema (DME).

Iridex Corporation have announced the results of a 10 year study confirming the safety and efficacy of using MicroPulse laser therapy for the treatment of diabetic macular oedema (DME).

The investigation, compiled by Dr Jeffrey K. Luttral et al., Ventura County Retina Vitreous Medical Group, California, USA, included 252 eyes with macular oedema. The study group consisted of 212 eyes with diabetic retinopathy and 40 eyes with branch retinal vein occlusion. Of the patients studied, 181 met the inclusion criteria and underwent subvisible MicroPulse laser treatment, with a follow-up of 10 years.

Dr Luttrall said, "MicroPulse laser therapy is an ideal first-line treatment for retinal vascular macular oedema because of its unique safety profile. Using specific laser parameters discussed in our recent study, MicroPulse laser treatment can be performed.

"I believe this laser treatment to be both absolutely harmless and as effective as conventional thermal retinal photocoagulation. The laser is able to produce the desired therapeutic effect without any measurable inflammation or damage to functional retinal tissue. Treatment can be initiated earlier, possibly improving long-term outcomes."